20-F
Annual Report (Foreign)
Cordyceps Sunshine Biotech Holdings Co., Ltd. RAJAF
0001213900-23-039368
- Filed
- May 15, 2023 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Outstanding | FY 2022 · Dec 31, 2022 | 111.12M sh |
| Capex | FY 2022 · Dec 31, 2022 | $475 |
| Capex | FY 2022 · Dec 31, 2020 | $1.11M |
| Short Term Debt | FY 2022 · Dec 31, 2022 | $57.11K |
| Cash And Equivalents | FY 2022 · Dec 31, 2021 | $99.68K |
| Cash And Equivalents | FY 2022 · Dec 31, 2020 | $294 |
| Current Liabilities | FY 2022 · Dec 31, 2021 | $2.92M |
| Current Liabilities | FY 2022 · Dec 31, 2020 | $2.41M |
| Total Liabilities | FY 2022 · Dec 31, 2021 | $3.54M |
| Total Liabilities | FY 2022 · Dec 31, 2020 | $2.84M |
| Current Assets | FY 2022 · Dec 31, 2021 | $1.13M |
| Current Assets | FY 2022 · Dec 31, 2020 | $949.01K |
| Total Assets | FY 2022 · Dec 31, 2021 | $3.26M |
| Total Assets | FY 2022 · Dec 31, 2020 | $2.83M |
| Gross Profit | FY 2022 · Dec 31, 2021 | −$176.21K |
| Gross Profit | FY 2022 · Dec 31, 2020 | $94.07K |
| Cost Of Revenue | FY 2022 · Dec 31, 2021 | $1.06M |
| Cost Of Revenue | FY 2022 · Dec 31, 2020 | $40.65K |
| Revenue | FY 2022 · Dec 31, 2021 | $879.32K |
| Revenue | FY 2022 · Dec 31, 2020 | $134.72K |
| Shares Diluted | FY 2022 · Dec 31, 2020 | 100M sh |
| Operating Cash Flow | FY 2022 · Dec 31, 2020 | −$130.55K |
| Eps Diluted | FY 2022 · Dec 31, 2020 | $0.00 |
| Eps Basic | FY 2022 · Dec 31, 2020 | $0.00 |
| Sga Expense | FY 2022 · Dec 31, 2020 | $78K |
| Net Income | FY 2022 · Dec 31, 2020 | −$13.48K |
| Net Income | FY 2022 · Dec 31, 2020 | −$13.48K |
| Operating Income | FY 2022 · Dec 31, 2020 | $8.73K |